Gilead Sciences Limited

Slavery and Human Trafficking Statement
for the financial year ending 31 March 2018

Introduction
Gilead Sciences Limited ("Gilead") is committed to maintaining the highest standards of legal and ethical conduct. We recognise the seriousness and importance of combatting modern slavery and human trafficking, and are committed to fully understanding and taking all appropriate action to address any slavery and human trafficking risks in our own business and in our supply chains.

Our business
Gilead's principal activity is the sale of pharmaceutical products. We sell pharmaceutical products manufactured by group companies to UK hospitals, retail pharmacies and other healthcare providers. We are based in the UK and carry on business in the UK.

Our policies and processes
We have policies and processes in place to address slavery and human trafficking risks in our supply chains. Our Supplier Code of Conduct contains anti-slavery and anti-human trafficking provisions. Our suppliers are required to adhere to this Code and we require our suppliers to contractually agree to comply with all applicable laws prohibiting human trafficking, slavery and child labour. We have provisions in our standard procurement contracts requiring compliance with the Modern Slavery Act 2015 (the "Act"). In our higher risk contracts, we have the right to audit our suppliers to ensure they comply with the Act.

Slavery and human trafficking risk assessment and review
We have appointed an independent consultant to conduct a review of slavery, human trafficking and other ethical risks in Gilead's business and supply chains and Gilead's management of those risks.

Modern Slavery Act
This statement is made pursuant to section 54(1) of the Act and constitutes Gilead's slavery and human trafficking statement for the financial year ending 31 March 2018. It has been approved by the board of directors and signed by a director of Gilead.

Brett Pletcher, General Counsel

Date: 12-24-18

2018
Introduction
Gilead Sciences International Limited ("Gilead") is committed to maintaining the highest standards of legal and ethical conduct. We recognise the seriousness and importance of combatting modern slavery and human trafficking, and are committed to fully understanding and taking all appropriate action to address any slavery and human trafficking risks in our own business and in our supply chains.

Our business
Gilead’s principal activity is the provision of technical and other support services. We provide these services to group companies in connection with the group’s pharmaceutical products for human healthcare. Our group manufactures pharmaceutical products and sells these to UK hospitals, retail pharmacies and other healthcare providers. Gilead is based in the UK and carries on business in the UK.

Our policies and processes
We have policies and processes in place to address slavery and human trafficking risks in our supply chains. Our Supplier Code of Conduct contains anti-slavery and anti-human trafficking provisions. Our suppliers are required to adhere to this Code and we require our suppliers to contractually agree to comply with all applicable laws prohibiting human trafficking, slavery and child labour. We have provisions in our standard procurement contracts requiring compliance with the Modern Slavery Act 2015 (the "Act"). In our higher risk contracts, we have the right to audit our suppliers to ensure they comply with the Act.

Slavery and human trafficking risk assessment and review
We have appointed an independent consultant to conduct a review of slavery, human trafficking and other ethical risks in Gilead’s business and supply chains and Gilead’s management of those risks.

Modern Slavery Act
This statement is made pursuant to section 54(1) of the Act and constitutes Gilead’s slavery and human trafficking statement for the financial year ending 31 March 2018. It has been approved by the board of directors and signed by a director of Gilead.

Brett Fletcher, General Counsel

Date: 12-24-2018

2018
Gilead Sciences Europe Limited

Slavery and Human Trafficking Statement
for the financial year ending 31 March 2018

Introduction.
Gilead Sciences Europe Limited ("Gilead") is committed to maintaining the highest standards of legal and ethical conduct. We recognise the seriousness and importance of combating modern slavery and human trafficking, and are committed to fully understanding and taking all appropriate action to address any slavery and human trafficking risks in our own business and in our supply chains.

Our business
Gilead's principal activity is the provision of technical and other support services. We provide these services to group companies in connection with the group's pharmaceutical products for human healthcare. Our group manufactures pharmaceutical products and sells these to UK hospitals, retail pharmacies and other healthcare providers. Gilead is based in the UK and carries on business in the UK.

Our policies and processes
We have policies and processes in place to address slavery and human trafficking risks in our supply chains. Our Supplier Code of Conduct contains anti-slavery and anti-human trafficking provisions. Our suppliers are required to adhere to this Code and we require our suppliers to contractually agree to comply with all applicable laws prohibiting human trafficking, slavery and child labour. We have provisions in our standard procurement contracts requiring compliance with the Modern Slavery Act 2015 (the "Act"). In our higher risk contracts, we have the right to audit our suppliers to ensure they comply with the Act.

Slavery and human trafficking risk assessment and review
We have appointed an independent consultant to conduct a review of slavery, human trafficking and other ethical risks in Gilead's business and supply chains and Gilead's management of those risks.

Modern Slavery Act
This statement is made pursuant to section 54(1) of the Act and constitutes Gilead's slavery and human trafficking statement for the financial year ending 31 March 2018. It has been approved by the board of directors and signed by a director of Gilead.

Date: 12-24-2018

Brett Fletcher, General Counsel